Czechia vs Latvia: HIV/AIDS deaths averted by antiretroviral therapy
Czechia
150 deaths
in 2022
Latvia
162.29 deaths
in 2024
Czechia rank
117th
Latvia rank
115th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Czechia
- Latvia
How they compare
Latvia currently reports 162.29 deaths against 150 deaths in Czechia, a difference of 12.29 deaths.
That makes Latvia's figure about 1.1 times Czechia's.
The two have swapped places 4 times across 33 shared years of data; in 1990 it was Latvia ahead.
Czechia ranks 117th and Latvia ranks 115th of 157 countries.
Across the 4 decades both report, Czechia averaged higher in 2 and Latvia in 2.
Head to head by decade
| Decade | Czechia | Latvia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 3.9 deaths | 0 deaths | 3.9 deaths | Czechia |
| 2000s | 41.6 deaths | 30.21 deaths | 11.39 deaths | Czechia |
| 2010s | 104.7 deaths | 138.04 deaths | 33.34 deaths | Latvia |
| 2020s | 148 deaths | 226.83 deaths | 78.83 deaths | Latvia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Czechia or Latvia?
- Latvia, at 162.29 deaths against 150 deaths in Czechia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Czechia and Latvia?
- 12.29 deaths, with Latvia ahead.
- How many years of comparable data are there for Czechia and Latvia?
- 33 years are reported by both, from 1990 to 2022.
- How do Czechia and Latvia rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Czechia ranks 117th and Latvia ranks 115th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.